Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target

The field of cancer therapy is rapidly moving forward with the development of numerous prospective new agents designed to inhibit cellular factors involved in signal transduction, cell proliferation, and the onset of apoptosis. At the core of these biological processes are transcription factors that are the functional mediators of these effects. Transcrip- tion factors are the downstream targets of numerous signal transduction pathways that are central to the process of car- cinogenesis. The Activator Protein-1 (AP-1) complex is one such factor that has a central role in multiple processes in- volved in tumorigenesis including proliferation, migration, invasion and metastasis. The focus of this review is, using AP- 1 as a model, to discuss transcription factors as targets for cancer therapy. The feasibility of targeted disruption of AP-1 by various agents such as dominant-negative mutants, small molecule inhibitors, transcription factor decoys (TFD), che- motherapeutic drugs, chemoprevention agents, siRNA and natural products will be explored.

[1]  M. Karin,et al.  Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor , 1987, Cell.

[2]  J. Ting,et al.  Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-κB- and AP-1-dependent mechanism , 2000, Cancer Immunology, Immunotherapy.

[3]  R. Gambari.  Biological activity and delivery of peptide nucleic acids (PNA)-DNA chimeras for transcription factor decoy (TFD) pharmacotherapy. , 2004, Current medicinal chemistry.

[4]  E. Wagner,et al.  AP-1 in mouse development and tumorigenesis , 2001, Oncogene.

[5]  M. Birrer,et al.  AP1 Regulation of Proliferation and Initiation of Apoptosis in Erythropoietin-Dependent Erythroid Cells , 1998, Molecular and Cellular Biology.

[6]  P. Angel,et al.  AP-1 subunits: quarrel and harmony among siblings , 2004, Journal of Cell Science.

[7]  M. Birrer,et al.  Reversible Regulation of the Transformed Phenotype of Ornithine Decarboxylase- and Ras-Overexpressing Cells by Dominant-Negative Mutants of c-Jun , 2004, Cancer Research.

[8]  L. Murphy,et al.  Enhanced c-jun activity alters responsiveness to medroxyprogesterone acetate in Ishikawa human endometrial carcinoma cells. , 1993, Molecular endocrinology.

[9]  R. Gambari,et al.  Transcription Factor Decoy Molecules Based on a Peptide Nucleic Acid (PNA)-DNA Chimera Mimicking Sp1 Binding Sites* , 2003, The Journal of Biological Chemistry.

[10]  N. Colburn,et al.  c‐jun and multistage carcinogenesis: Association of overexpression of introduced c‐jun with progression toward a neoplastic endpoint in mouse JB6 cells sensitive to tumor promoter‐induced transformation , 1995, Molecular carcinogenesis.

[11]  D. Raha,et al.  Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer , 2005, BMC Cancer.

[12]  M. Karin,et al.  Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73 , 1991, Nature.

[13]  M. Birrer,et al.  AP-1 complexes containing cJun and JunB cause cellular transformation of Rat1a fibroblasts and share transcriptional targets , 2003, Oncogene.

[14]  M. Birrer,et al.  Suppression of oncogene-induced transformation by a deletion mutant of c-jun. , 1993, Oncogene.

[15]  F. Jurnak,et al.  Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor , 2005, Molecular Cancer Therapeutics.

[16]  F. McCormick,et al.  Killing time for cancer cells , 2005, Nature Reviews Cancer.

[17]  E. Bossy‐Wetzel,et al.  Induction of apoptosis by the transcription factor c‐Jun , 1997, The EMBO journal.

[18]  I. Gromova,et al.  Immediate and Delayed Effects of E-Cadherin Inhibition on Gene Regulation and Cell Motility in Human Epidermoid Carcinoma Cells , 2005, Molecular and Cellular Biology.

[19]  K. Belguise,et al.  FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells , 2005, Oncogene.

[20]  J. Licht,et al.  Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells , 2004, Nature Medicine.

[21]  B. Aggarwal,et al.  From chemoprevention to chemotherapy: common targets and common goals , 2004, Expert opinion on investigational drugs.

[22]  M. Birrer,et al.  Identification of domains of c-Jun mediating androgen receptor transactivation , 1998, Oncogene.

[23]  Dawn White,et al.  Differential regulation of protein expression, growth and apoptosis by natural and synthetic retinoids , 2003, Journal of cellular biochemistry.

[24]  P. Sassone-Corsi,et al.  fos and jun interaction: The role of the leucine zipper , 1989, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[25]  P. Brown,et al.  cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype , 1999, Oncogene.

[26]  M. Karin,et al.  Three distinct signalling responses by murine fibroblasts to genotoxic stress , 1996, Nature.

[27]  M. Hecker,et al.  Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity. , 2004, The Journal of allergy and clinical immunology.

[28]  J. Visvader,et al.  Fos-Jun interaction: mutational analysis of the leucine zipper domain of both proteins. , 1989, Genes & development.

[29]  T. Chiles,et al.  Transient stimulation of the c-Jun-NH2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. , 1998, Cancer research.

[30]  M. Karin.  The regulation of AP-1 activity by mitogen-activated protein kinases. , 1996, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[31]  F. D’Acquisto,et al.  Nuclear factor-κB activation mediates inducible nitric oxide synthase expression in carrageenin-induced rat pleurisy , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[32]  J. Darnell.  Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.

[33]  B. Neyns,et al.  Alteration of Jun proto‐oncogene status by plasmid transfection affects growth of human ovarian cancer cells , 1999, International journal of cancer.

[34]  M. Karin,et al.  AP-1 as a regulator of cell life and death , 2002, Nature Cell Biology.

[35]  K. Shirasuna,et al.  Inhibition of epidermal growth factor‐induced invasion by dexamethasone and AP‐1 decoy in human squamous cell carcinoma cell lines , 2002, Journal of cellular physiology.

[36]  R. Gambari,et al.  Interaction of the Human NF-κB p52 Transcription Factor with DNA-PNA Hybrids Mimicking the NF-κB Binding Sites of the Human Immunodeficiency Virus Type 1 Promoter* , 1999, The Journal of Biological Chemistry.

[37]  E. Zandi,et al.  AP-1 function and regulation. , 1997, Current opinion in cell biology.

[38]  M. Birrer,et al.  Constitutive cJun expression induces partial macrophage differentiation in U-937 cells. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[39]  T. Chambers,et al.  Subcellular localization as a limiting factor for utilization of decoy oligonucleotides. , 2004, Nucleic acids research.

[40]  M. Birrer,et al.  Mechanism of action of a dominant-negative mutant of c-Jun. , 1994, Oncogene.

[41]  M. Birrer,et al.  The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. , 2001, Cancer research.

[42]  M. Birrer,et al.  Use of transcription factors as agents and targets for drug development. , 1996, Oncology.

[43]  J. Grandis,et al.  Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond. , 2005, Current pharmaceutical design.

[44]  H. Stein,et al.  Aberrantly expressed c‐Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF‐κB , 2002, The EMBO journal.

[45]  H. Wang,et al.  Expression of Jun family members in human colorectal adenocarcinoma. , 2000, Carcinogenesis.

[46]  A. Sabichi,et al.  Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[47]  M. Karin,et al.  From JNK to Pay Dirt: Jun Kinases, their Biochemistry, Physiology and Clinical Importance , 2005, IUBMB life.

[48]  Y. Kaneda,et al.  Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo , 2004, Gene Therapy.

[49]  A. Sabichi,et al.  Identification of cJun-responsive genes in Rat-1a cells using multiple techniques: increased expression of stathmin is necessary for cJun-mediated anchorage-independent growth , 2003, Oncogene.

[50]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.

[51]  R. Bravo,et al.  The jun and fos protein families are both required for cell cycle progression in fibroblasts , 1991, Molecular and cellular biology.

[52]  J. Baselga,et al.  Targeting Tyrosine Kinases in Cancer: The Second Wave , 2006, Science.

[53]  N. Colburn,et al.  A dominant negative c-jun specifically blocks okadaic acid-induced skin tumor promotion. , 2002, Cancer research.

[54]  T. Cruz,et al.  Inhibition of activator protein 1 activity by paclitaxel suppresses interleukin-1-induced collagenase and stromelysin expression by bovine chondrocytes. , 1998, Arthritis and rheumatism.

[55]  B. Prusty,et al.  Constitutive activation of transcription factor AP‐1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP‐1 activity in HeLa cells by curcumin , 2005, International journal of cancer.

[56]  A. Papavassiliou,et al.  Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas. , 2003, Bone.

[57]  D. Spandidos,et al.  Human lung and bladder carcinoma tumors as compared to their adjacent normal tissue have elevated AP-1 activity associated with the retinoblastoma gene promoter. , 1993, Anticancer research.

[58]  M. Olive,et al.  A Dominant Negative to Activation Protein-1 (AP1) That Abolishes DNA Binding and Inhibits Oncogenesis* , 1997, The Journal of Biological Chemistry.

[59]  P. Vogt,et al.  Jun, the oncoprotein , 2001, Oncogene.

[60]  P. Dent,et al.  Inhibition of the mitogen activated protein kinase pathway potentiates radiation-induced cell killing via cell cycle arrest at the G2/M transition and independently of increased signaling by the JNK/c-Jun pathway. , 2000, International journal of oncology.

[61]  H. Ciolino,et al.  Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells , 1999, Breast Cancer Research and Treatment.

[62]  K. Matsushima,et al.  Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter , 1997, Molecular and cellular biology.

[63]  M. Birrer,et al.  Alterations in differentiation and apoptosis induced by bufalin in cJun overexpressing U-937 cells. , 1998, International journal of oncology.

[64]  Dirk Bohmann,et al.  Reduced Ubiquitin-Dependent Degradation of c-Jun After Phosphorylation by MAP Kinases , 1997, Science.

[65]  M. Olive,et al.  Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines , 2002, Cancer Gene Therapy.

[66]  Gee,et al.  Impact of activation of MAP kinase family members on endocrine response and survival in clinical breast cancer , 2000, European journal of cancer.

[67]  M. Skinner,et al.  Transcriptional activation and transformation by FosB protein require phosphorylation of the carboxyl-terminal activation domain , 1997, Molecular and cellular biology.

[68]  R. Bravo,et al.  c-JUN, JUN B, and JUN D differ in their binding affinities to AP-1 and CRE consensus sequences: effect of FOS proteins. , 1991, Oncogene.

[69]  M. Bogoyevitch,et al.  Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. , 2004, Biochimica et biophysica acta.

[70]  M. Birrer,et al.  The role of jun and fos gene family members in 12-O-tetradecanoylphorbol-13-acetate induced hemopoietic differentiation. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[71]  J. K. Kundu,et al.  Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. , 2004, Mutation research.

[72]  Roberto Gambari,et al.  New trends in the development of transcription factor decoy (TFD) pharmacotherapy. , 2004, Current drug targets.

[73]  R. Vento,et al.  JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways , 2006, Apoptosis.

[74]  R. Gambari,et al.  Peptide nucleic acids (PNA)-DNA chimeras targeting transcription factors as a tool to modify gene expression. , 2004, Current drug targets.

[75]  D. Taub,et al.  A dominant negative mutant of jun blocking 12‐O‐tetradecanoylphorbol‐13‐acetate–induced invasion in mouse keratinocytes , 1997, Molecular carcinogenesis.

[76]  B. Lambrecht,et al.  Treatment of experimental asthma by decoy-mediated local inhibition of activator protein-1. , 2005, American journal of respiratory and critical care medicine.

[77]  N. Colburn,et al.  Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[78]  P. Vogt.  The story of Jun. , 1995, Archives of biochemistry and biophysics.

[79]  K. Milde-Langosch,et al.  Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators , 2001, Journal of Cancer Research and Clinical Oncology.

[80]  A. Kong,et al.  Modulation of AP-1 by Natural Chemopreventive Compounds in Human Colon HT-29 Cancer Cell Line , 2004, Pharmaceutical Research.

[81]  M. Metzger,et al.  Downregulation of TNF-α and VEGF expression by Sp1 decoy oligodeoxynucleotides in mouse melanoma tumor , 2003, Gene Therapy.

[82]  P. Vogt,et al.  Oncogenic transformation by Jun: role of transactivation and homodimerization. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[83]  R. Davis,et al.  Signal transduction by the c-Jun N-terminal kinase. , 1999, Biochemical Society symposium.